Effects of Intranasal Administration of Oxytocin and Vasopressin on Social Cognition and Potential Routes and Mechanisms of Action.
G protein-coupled receptors
blood–brain barrier
intranasal administration
oxytocin
social cognition
vagus
vasopressin
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
29 Jan 2022
29 Jan 2022
Historique:
received:
06
01
2022
revised:
24
01
2022
accepted:
27
01
2022
entrez:
26
2
2022
pubmed:
27
2
2022
medline:
27
2
2022
Statut:
epublish
Résumé
Acute and chronic administration of intranasal oxytocin and vasopressin have been extensively utilized in both animal models and human preclinical and clinical studies over the last few decades to modulate various aspects of social cognition and their underlying neural mechanisms, although effects are not always consistent. The use of an intranasal route of administration is largely driven by evidence that it permits neuropeptides to penetrate directly into the brain by circumventing the blood-brain barrier, which has been considered relatively impermeable to them. However, this interpretation has been the subject of considerable debate. In this review, we will focus on research in both animal models and humans, which investigates the different potential routes via which these intranasally administered neuropeptides may be producing their various effects on social cognition. We will also consider the contribution of different methods of intranasal application and additionally the importance of dose magnitude and frequency for influencing G protein-coupled receptor signaling and subsequent functional outcomes. Overall, we conclude that while some functional effects of intranasal oxytocin and vasopressin in the domain of social cognition may result from direct penetration into the brain following intranasal administration, others may be contributed by the neuropeptides either entering the peripheral circulation and crossing the blood-brain barrier and/or producing vagal stimulation via peripheral receptors. Furthermore, to complicate matters, functional effects via these routes may differ, and both dose magnitude and frequency can produce very different functional outcomes and therefore need to be optimized to produce desired effects.
Identifiants
pubmed: 35214056
pii: pharmaceutics14020323
doi: 10.3390/pharmaceutics14020323
pmc: PMC8874551
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Front Endocrinol (Lausanne). 2017 Sep 22;8:220
pubmed: 29018407
Neuropsychopharmacology. 2014 Apr;39(5):1102-14
pubmed: 24190025
Mol Psychiatry. 2021 Jan;26(1):80-91
pubmed: 32807845
Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7650-4
pubmed: 27325780
Neuropsychopharmacology. 2021 Jan;46(2):297-304
pubmed: 32450570
Curr Top Behav Neurosci. 2018;35:3-29
pubmed: 28812263
Neuroimage. 2021 Feb 15;227:117668
pubmed: 33359350
Neuroimage. 2017 Nov 15;162:127-137
pubmed: 28877512
Prog Neurobiol. 2008 Jan;84(1):1-24
pubmed: 18053631
Mol Psychiatry. 2021 May 25;:
pubmed: 34035479
Psychoneuroendocrinology. 2016 Jul;69:180-8
pubmed: 27107209
Mol Psychiatry. 2016 Sep;21(9):1225-31
pubmed: 26503762
Neuropsychopharmacology. 2019 Jan;44(1):97-110
pubmed: 29968846
Transl Psychiatry. 2020 Jul 12;10(1):227
pubmed: 32655132
Curr Top Behav Neurosci. 2018;35:389-420
pubmed: 28812271
Mol Psychiatry. 2018 Jan;23(1):115-122
pubmed: 28289281
Psychoneuroendocrinology. 2012 Jan;37(1):87-93
pubmed: 21641726
Nat Commun. 2020 Jun 3;11(1):2783
pubmed: 32494001
Nat Commun. 2020 Mar 3;11(1):1160
pubmed: 32127545
Psychopharmacology (Berl). 2006 Apr;185(2):218-25
pubmed: 16418825
Neuropsychopharmacology. 2003 Jan;28(1):193-8
pubmed: 12496956
Biol Psychiatry. 2013 Aug 1;74(3):180-8
pubmed: 23079235
Transl Psychiatry. 2021 Feb 4;11(1):94
pubmed: 33542175
Prog Neurobiol. 2022 Apr;211:102239
pubmed: 35122880
Neuropsychopharmacology. 2019 Jan;44(2):306-313
pubmed: 30323359
Peptides. 2020 Jun;128:170312
pubmed: 32298773
Am J Physiol Regul Integr Comp Physiol. 2015 Mar 1;308(5):R360-9
pubmed: 25540101
Commun Biol. 2020 Feb 13;3(1):70
pubmed: 32054984
Physiol Behav. 2019 Dec 1;212:112701
pubmed: 31629768
Neuropsychopharmacology. 2019 Mar;44(4):749-756
pubmed: 30390065
Biol Psychiatry. 1996 Mar 1;39(5):332-40
pubmed: 8704064
Nat Commun. 2019 Feb 8;10(1):668
pubmed: 30737392
Sci Rep. 2013 Dec 06;3:3440
pubmed: 24310737
Annu Rev Psychol. 2014;65:17-39
pubmed: 24050183
Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):8119-8124
pubmed: 28696286
Transl Psychiatry. 2015 Jul 14;5:e602
pubmed: 26171983
Drug Deliv Transl Res. 2021 Jan 25;:
pubmed: 33491126
Drug Deliv Transl Res. 2013 Feb;3(1):42-62
pubmed: 23316447
Front Neurosci. 2012 Dec 07;6:174
pubmed: 23233832
Drug Deliv. 2014 Mar;21(2):75-86
pubmed: 24102636
Biol Psychiatry. 2016 Feb 1;79(3):243-50
pubmed: 26049207
PLoS One. 2014 Aug 18;9(8):e103677
pubmed: 25133536
Int Forum Allergy Rhinol. 2019 Jul;9(7):746-758
pubmed: 30821929
Curr Top Behav Neurosci. 2018;35:321-348
pubmed: 28864976
Endocrinol Exp. 1985 Mar;19(1):29-37
pubmed: 3872788
Laryngoscope. 2006 Mar;116(3):466-72
pubmed: 16540911
Brain Res. 1983 Feb 28;262(1):143-9
pubmed: 6831225
Brain Res Bull. 2018 Oct;143:155-170
pubmed: 30449731
NeuroRx. 2005 Jan;2(1):3-14
pubmed: 15717053
J Neurodev Disord. 2018 Mar 27;10(1):12
pubmed: 29587625
Pharmacol Res. 2019 Aug;146:104325
pubmed: 31233803
Nat Neurosci. 2002 Jun;5(6):514-6
pubmed: 11992114
J Pharm Pharmacol. 1995 Jul;47(7):571-5
pubmed: 8568623
Neuropsychopharmacology. 2020 Jun;45(7):1134-1140
pubmed: 31785587
Eur J Neurosci. 2021 Oct;54(7):6374-6381
pubmed: 34498316
Neuroscience. 2018 Nov 10;392:241-251
pubmed: 30071278
Transl Psychiatry. 2020 May 12;10(1):142
pubmed: 32398642
Commun Biol. 2019 Feb 25;2:76
pubmed: 30820471
Biomed Res Int. 2019 Mar 28;2019:4602651
pubmed: 31032346
Sci Rep. 2016 Nov 15;6:35054
pubmed: 27845765
Circ Res. 1999 Feb 19;84(3):365-70
pubmed: 10024312
Adv Drug Deliv Rev. 2012 May 15;64(7):614-28
pubmed: 22119441
Front Behav Neurosci. 2015 Sep 17;9:245
pubmed: 26441574
Psychol Med. 2020 Dec 04;:1-10
pubmed: 33272333
Psychother Psychosom. 2022 Jan 27;:1-12
pubmed: 35086102
Psychoneuroendocrinology. 2011 Sep;36(8):1114-26
pubmed: 21429671
Pharmacol Res. 2019 Aug;146:104324
pubmed: 31238093
Biol Psychiatry. 2016 Apr 15;79(8):693-705
pubmed: 25499958
Neuropsychopharmacology. 2017 Jun;42(7):1420-1434
pubmed: 27995932
Biol Psychol. 2011 Mar;86(3):174-80
pubmed: 21126557
PLoS One. 2012;7(8):e44014
pubmed: 22937145
Physiol Rev. 1988 Oct;68(4):1248-84
pubmed: 3054948
Br J Pharmacol. 2021 Apr 4;:
pubmed: 33817785
Psychoneuroendocrinology. 2013 May;38(5):612-25
pubmed: 23265311
Psychoneuroendocrinology. 2013 Oct;38(10):1985-93
pubmed: 23579082
PLoS One. 2015 Dec 15;10(12):e0145104
pubmed: 26669935
Clin Sci (Lond). 1984 Nov;67(5):473-81
pubmed: 6236929
Physiol Rev. 2018 Jul 1;98(3):1805-1908
pubmed: 29897293
Biol Psychiatry. 2017 Dec 15;82(12):885-894
pubmed: 28629540
Transl Psychiatry. 2017 May 23;7(5):e1136
pubmed: 28534875
Biol Psychiatry. 2007 Feb 15;61(4):498-503
pubmed: 16904652
Psychoneuroendocrinology. 2021 Nov;133:105412
pubmed: 34537624
J Psychiatr Res. 2003 Nov-Dec;37(6):443-55
pubmed: 14563375
Front Pharmacol. 2021 Apr 20;12:652473
pubmed: 33959017
Psychoneuroendocrinology. 2014 Jul;45:49-57
pubmed: 24845176
Pharmaceutics. 2021 Jul 16;13(7):
pubmed: 34371778
Eur Surg Res. 2008;40(1):34-40
pubmed: 17890865
Transl Psychiatry. 2015 Feb 10;5:e507
pubmed: 25668435
Sci Transl Med. 2019 May 8;11(491):
pubmed: 31043522
Mol Pharm. 2018 Mar 5;15(3):1105-1111
pubmed: 29338251
Nat Rev Neurosci. 2011 Aug 19;12(9):524-38
pubmed: 21852800
Horm Behav. 2018 Jun;102:85-92
pubmed: 29750971
Cell Signal. 2018 Jan;41:9-16
pubmed: 28137506
Chem Commun (Camb). 2018 Jul 17;54(58):8120-8123
pubmed: 29974895